Eyepoint Pharmaceuticals Inc Overview
Industry: Biotechnology
Sector: Healthcare
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States, China, and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU for the treatment of postoperative inflammation. The company's pipeline leverages its Durasert technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal treatment that is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals, Inc., a pharmaceutical company, engages in developing and commercializing therapeutics to enhance the lives of patients with serious eye disorders in the United States, China, and the United Kingdom. Its commercial products include YUTIQ for the treatment of chronic non-inf Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Eyepoint Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $0.7M (-97% YoY). Net loss was -$84.8M. Cash was $223M.
Revenue
$0.7M
-97% YoY
Net loss
-$84.8M
reported
Cash
$223M
reported
What changed
- Revenue -97% YoY to $0.7M.
Guidance / outlook
We expect the cash, cash equivalents, and marketable securities as of March 31, 2026, will enable us to fund operations into the fourth quarter of 2027 beyond key milestones for the Phase 3 wet AMD program in 2026. Conference Call Information EyePoint will host a conference call today at 8:30 a.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 07, 2026
SEC filing
8-K
May 06, 2026
SEC filing
10-K
Mar 05, 2026
SEC filing
8-K
Mar 04, 2026
Earnings release
Earnings release
Mar 04, 2026
SEC filing
8-K
Jan 07, 2026
SEC filing
10-Q
Nov 06, 2025
SEC filing
8-K
Nov 05, 2025
Earnings release
Earnings release
Nov 05, 2025
SEC filing
8-K
Oct 14, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Form 144 EyePoint For: 21 July By Investing.com
Headline from Investing.com Canada: Form 144 EyePoint For: 21 July By Investing.com.
EyePoint to pay $4.6M to settle kickback claims (update) (EYPT)
Headline from Seeking Alpha: EyePoint to pay $4.6M to settle kickback claims (update) (EYPT).
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Headline from GlobeNewswire: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4).
Stifel initiates EyePoint stock with buy rating on retinal drug potential
Headline from Investing.com: Stifel initiates EyePoint stock with buy rating on retinal drug potential.
EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer
Headline from Yahoo Finance: EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer.
Earnings Per Share
Score 3.00/5
Eyepoint Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 1.00/5
Eyepoint Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 1.30/5
Eyepoint Pharmaceuticals Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 3.00/5
Eyepoint Pharmaceuticals Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios